<DOC>
	<DOCNO>NCT01393899</DOCNO>
	<brief_summary>This study investigate safety efficacy CP-690,550 adult patient moderate severe Crohn 's disease complete double-blind induction treatment Study A3921083 achieve clinical response-100 and/or clinical remission ( CDAI &lt; 150 ) Week 8 .</brief_summary>
	<brief_title>The Safety And Efficacy Of Maintenance Therapy With CP-690,550</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Subjects meet study entry criterion , complete Week 8 visit Induction Study A3921083 . Subjects achieve clinical response100 ( reduction CDAI 100 point ) and/or clinical remission ( CDAI &lt; 150 ) Study A3921083 . Women childbearing potential must test negative pregnancy prior study enrolment . Subjects major protocol violation ( determine Sponsor ) A3921083 study . Subjects likely require type surgery study period . Fecal culture/toxin assay indicate presence pathogenic infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>tofacitinib</keyword>
	<keyword>Xeljanz</keyword>
	<keyword>CP-690,550</keyword>
	<keyword>maintenance therapy</keyword>
</DOC>